Amylyx Pharmaceuticals, Inc.

AMLX

$1.30B

Small Cap

NASDAQBiotechnology🇺🇸North America123 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

12w

Drug Pipeline

Drug Name	Phase	Indication	Designations
AMX0035	Phase 3	Amyotrophic Lateral Sclerosis	-
Avexitide	Phase 3	Post Bariatric Hypoglycemia	-
Placebo	Phase 2	Alzheimer Disease	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Avexitide Phase 3 Results Expected

March 2026~Avexitide

Primary completion for Avexitide trial (NCT06747468) in Post Bariatric Hypoglycemia

Source

⭐Phase 3

AMX0035 Phase 3 Results Expected

Apr 1, 2026AMX0035

Primary completion for AMX0035 trial (NCT06122662) in Progressive Supranuclear Palsy

Source

Regulatory Approvals

AMLX News

Amylyx Pharmaceuticals, Inc.

AMLX

$1.30B

Small Cap

NASDAQBiotechnology🇺🇸North America123 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

12w

Drug Pipeline

Drug Name	Phase	Indication	Designations
AMX0035	Phase 3	Amyotrophic Lateral Sclerosis	-
Avexitide	Phase 3	Post Bariatric Hypoglycemia	-
Placebo	Phase 2	Alzheimer Disease	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Avexitide Phase 3 Results Expected

March 2026~Avexitide

Primary completion for Avexitide trial (NCT06747468) in Post Bariatric Hypoglycemia

Source

⭐Phase 3

AMX0035 Phase 3 Results Expected

Apr 1, 2026AMX0035

Primary completion for AMX0035 trial (NCT06122662) in Progressive Supranuclear Palsy

Source

Regulatory Approvals

AMLX News